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Abstract
Objectives—To describe first dose and steady-state pharmacokinetics (PK) of dolutegravir
(DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal fluid
(RF) of healthy HIV negative men.
Design—A Phase 1, open label, PK study that enrolled 12 healthy men taking DTG 50mg daily
for 8d.
Methods—Eleven paired BP samples and 3 SF and RF samples were collected over 24h
following first (PK1) and multiple (PK2) dosing. RT biopsies were collected at 1 of 6 time points
at PK1 and PK2 to generate composite PK profiles. DTG concentrations were analyzed by
validated LC-MS/MS. Noncompartmental PK analysis was conducted with Phoenix WinNonlin
v6.3 and Spearman Rank Correlations determined using SAS v9.3.
Results—BP AUCs were similar to previous reports and C24h was 6 - 34 fold greater than the
protein adjusted (PA) IC90 of 64 ng/mL. SF exposures were ～7% of BP, and below the PA-IC90.
RT exposures were 17% of BP and ～2-fold greater than PA-IC90. RF AUCs were ～2-5% of RT
Corresponding Author/Reprints: Angela D.M. Kashuba, BScPhm, PharmD, DABCP, 3318 Kerr Hall CB#7569, University of North
Carolina at Chapel Hill, Chapel Hill, NC 27599-7569, Phone: (919) 966-9998 Fax: (919) 966-0644, akashuba@unc.edu.
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, USA, Mar 3-6, 2013.
Conflicts of Interest: Financial support for the study was provided by Shionogi-Viiv Healthcare. Angela Kashuba's spouse is
employed by GlaxoSmithKline. The remaining authors have no additional conflicts to declare.
Author Contributions: BN Greener- subject recruitment and study visit conduct, pharmacokinetic and statistical data analysis, and
primary author of manuscript
KB Patterson- study visit conduct, clinical study safety officer, critical review of manuscript
HMA Prince- subject recruitment and study visit conduct, critical review of manuscript
C Sykes- analytical data analysis, critical review of manuscript
JL Adams- study visit conduct, pharmacokinetic and statistical data analysis, critical review of manuscript
JB Dumond- pharmacokinetic and statistical data analysis, critical review of manuscript
ES Dellon- study visit conduct, critical review of manuscript
RD Madanick- study visit conduct, critical review of manuscript
NJ Shaheen- study visit conduct, critical review of manuscript
MS Cohen- study design, critical review of manuscript
ADM Kashuba- study design, analytical and pharmacokinetic data analysis, funding, critical review of manuscript
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2014 September 01.
Published in final edited form as:













and did not correlate with RT (Rho =0.43, p=0.17). Accumulation of DTG with multiple dosing
was observed in BP, SF, and RT.
Conclusions—DTG BP PK were consistent with previously published values. SF
concentrations were <7% BP, with SF C24h below the PA-IC90. However, SF protein binding was
not measured. Although the AUC of DTG in RT was <20% BP, RT C24h remained ～ 2-fold higher
than the PA-IC90. RF was not a strong surrogate for RT concentrations.
Keywords
dolutegravir; S/GSK1349572; integrase inhibitor; colorectal tissue; seminal fluid; male genital
tract
Introduction
Dolutegravir (DTG) is an integrase strand transfer inhibitor currently in phase 3 clinical
development for HIV-1 treatment. DTG has potent antiviral activity, a predictable
pharmacokinetic (PK) profile in blood plasma (BP) with low intersubject variability (CV%
9-41) compared to raltegravir, and is well tolerated [1-4]. DTG is primarily metabolized by
UGT1A1 with a minor route via CYP3A and is also a P-glycoprotein (P-gp) substrate. The
12-15 hour elimination half-life supports once daily dosing and allows for sustained
antiretroviral activity without the need for pharmacokinetic boosting [1,2]. The recent
SPRING-2 study demonstrated non-inferiority to raltegravir: 88% and 85% of patients,
respectively, achieved HIV-1 RNA <50 copies/mL at 48 weeks [4].
The exposure-response relationship for antiretroviral agents (ARV) including DTG and
other integrase inhibitors is best described by trough concentrations at 24 hours (C24h) [2,5].
Maintenance of DTG concentrations above the protein-adjusted concentration required for
90% viral inhibition (PA-IC90) across the dosing interval has been used to assess activity.
DTG at a dose of 50 mg achieves a steady-state C24h that is approximately 13-fold greater
than the PA-IC90 of 64 ng/mL for wild type virus [1].
The purpose of this study is to describe first dose and steady state pharmacokinetics of DTG
in seminal fluid (SF), colorectal tissue (RT) and rectal mucosal fluid (RF) compared to
blood plasma (BP) in HIV-1 negative men. Although current antiretroviral regimens can
decrease blood plasma HIV RNA to <50 copies/mL, the risk of HIV-1 transmission remains,
as viral shedding in the male genital tract and colorectum may still occur [6-12]. While a
low HIV-1 plasma viral load reduces the risk of heterosexual transmission events, less is
known regarding the risk associated with incomplete viral suppression at local sites of
transmission [13-14]. Pharmacokinetic requirements to prevent local transmission have not
yet been elucidated; however, drugs that achieve high exposure at sites of transmission are
expected to make ideal candidates for pre-exposure prophylaxis and treatment as prevention
applications by conferring better protection [15]. Understanding the pharmacokinetic
behavior of DTG in multiple male biological compartments will inform its role in preventing
local viral replication in HIV-infected men as well as its potential in protecting mucosal
surfaces against HIV infection. This is the first study of male genital tract and colorectal
tissue antiretroviral pharmacokinetics to be performed prior to market approval.
Methods
Study Design
This single center, open-label, prospective PK study evaluated 12 healthy adult males
between December 2011 and May 2012. The sample size was chosen to generate PK data
adequate for understanding penetration of DTG into the gastrointestinal and genital tract.
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Subjects received 50 mg oral DTG once daily for 8 days with intensive PK sampling visits
after a single dose and at steady state. PK sampling was performed after 7 and 8 doses to
allow appropriate SF volumes to be collected and to accommodate procurement of RF.
Visits were conducted at the University of North Carolina at Chapel Hill (UNC) in the
Clinical and Translational Research Center. The study was approved by the UNC
Biomedical Institutional Review Board, operated under FDA IND # 113,425, and was
registered with the NIH clinical trial registry (NCT01459315). Dolutegravir (DTG) tablets
were provided by ViiV Healthcare. All participants provided written informed consent
before commencing study procedures.
Subject Selection
Screening procedures were initiated within 42 days of administration of DTG. Screening
procedures consisted of a complete medical history and physical examination, 12-lead
electrocardiogram (ECG) with cardiology interpretation and comprehensive laboratory
studies (complete blood count with differential, liver function tests, serum chemistries,
urinalysis, and urine toxicology). Subjects were screened for active hepatitis B and hepatitis
C, HIV, syphilis, gonorrhea, chlamydia and HSV-2. Subjects were eligible to participate if
they were natural born males between 18-49 years of age, inclusive at the date of screening,
and had a Body Mass Index (BMI) 18-30kg/m2 with total body weight greater than 50kg.
Subjects were required to have fully intact genital and gastrointestinal tracts, have no known
medication allergies, and not have participated in another drug research study within the
prior four months. Subjects were excluded for any clinically significant abnormal lab value,
physical examination finding or clinical condition that would interfere with study activities
including disorders of the gastrointestinal tract or genital tract. Subjects were required to
stop all prescription and nonprescription medications 7 days before and herbal supplements
14 days before study enrollment, and medications could not be restarted until study
completion. Subjects were limited to consumption of less than 14 alcoholic beverages per
week, and acetaminophen at doses of ≤1g/day.
Subjects abstained from sexual activity or use of intra-rectal products from 72 hours before
dosing until follow-up. Subjects abstained from alcohol, Seville oranges and grapefruit juice
for 7 days prior to administration of DTG. Additionally, subjects were required to fast for 8
hours prior to DTG administration at PK sampling visits, adhere to a low fiber diet 3 days
prior, and a clear liquid diet 12 hours prior to biopsy procedures. Subjects were sequentially
assigned to SF and RF collection and RT biopsy times at screening.
Safety Assessments
Vital signs and clinical laboratory testing including a complete lipid panel, serum
chemistries and CBC with differential were performed at every visit. Subjects underwent
adverse event (AE) assessment on each PK visit day and daily by telephone between
inpatient visits. Adverse events were captured by subject self-reporting and completion of a
standardized assessment form. All AEs and laboratory values were graded by the study
physician according to the National Institute of Health Division of Allergy and Infectious
Disease (DAIDS) grading criteria [16]. Subjects were followed until all AEs resolved.
Sample Collection and Processing
Subjects were admitted to the UNC CTRC at least 2 hours prior to their 50 mg DTG dose on
day 1 and on day 7. BP was collected in 3mL K2EDTA tubes (BD Diagnostics, Franklin
Lakes, NJ) pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours post-dose on days 1, 7,
and 8. Rectal mucosal fluid and seminal fluid were self-collected pre-dose and at two time
points per subject on day 1 and three time points per subject on both day 7 and 8 (either 1, 3,
6, 12, 18, or 24 hours post-dose). RF was self-collected by subjects following instruction via
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insertion of a Dacron swab approximately 1-2 inches into the rectum for 1-2 minutes. For SF
collections, participants were provided with self-care instructions, lubricant, visual aids, and
a private room then given 30 minutes to procure a sample in a sterile container by
masturbation. Colorectal tissue was collected at a single time point per subject (either 1, 3, 6,
12, 18, or 24 hours postdose) on day 1 and on day 7 or 8. Non-targeted endoscopic cold
biopsies were taken by flexible sigmoidoscopy (NJS, RDM, ESD) at approximately 10 cm
from the anal verge using a spiral approach with 2.8 mm Radial Jaw™ 4 large capacity
biopsy forceps (Boston Scientific, Natick, MA). Ten pinch biopsies were taken at each
procedure. Subjects were considered evaluable if they were able to provide all RT and 80%
of BP, SF and RF samples, excluding pre-dose samples but including 24 hour samples.
K2EDTA tubes were stored on ice and processed within 1 hour of collection by
centrifugation at 3000 rpm at 4°C for 10 minutes. BP was transferred to 2 mL cryovials and
frozen at -80°C until analysis. RF was frozen immediately in 15 mL conical tubes following
collection at -80°C. SF was left to liquefy at room temperature for approximately 1 hour
then transferred to 15 mL conical tubes and centrifuged at 5000 rpm at 4°C for 15 minutes.
Seminal plasma was then transferred to 2 mL cryovials and frozen at -80°C. RT was flash
frozen in liquid nitrogen and stored at -80°C.
Dolutegravir Quantification
Quantification of drug concentrations in all matrices was completed using LC-MS/MS
methods validated by the UNC Center for AIDS Research Clinical Pharmacology and
Analytical Chemistry Core. DTG in BP was extracted from calibration standards, quality
control samples, and study samples using protein precipitation followed by LC-MS/MS
analysis. Dolutegravir-d715N (DTG-IS) was used as an internal standard. Thirty microliters
of plasma was mixed with 600 μL of acetonitrile containing the internal standard. Following
vortex and centrifugation steps, the supernatant was diluted with 50:50 methanol:water prior
to LC-MS/MS analysis. DTG was eluted from a Varian (Agilent) Pursuit Diphenyl (2.1 × 50
mm, 3 μm particle size) analytical column. Data were collected using a Sciex Analyst
Chromatography Software on an AB Sciex API-5000 triple quadrupole mass spectrometer
(AB Sciex, Foster City, CA). Calibration curves were obtained by using a 1/concentration2
weighted linear regression of analyte:internal standard peak area ratio vs. concentration. The
calibration range of this assay was 20 to 20,000 ng/mL. All calibrators and quality control
samples were within 15% of the nominal value for both within-day and between-day runs.
Within-day and between-day precision was < 15%. Recoveries of DTG and its internal
standard seen with this methodology were approximately 100%.
DTG was quantified in SF by similar methodology. Thirty microliters of seminal plasma
was mixed with 270 μL of acetonitrile containing the internal standard. Following vortex
and centrifugation steps, the supernatant was diluted with 50:50 methanol:water and
analyzed by LC-MS/MS using the same method as described for BP. The calibration range
of the assay was 1 to 1000 ng/mL. All calibrators and quality control samples were within
15% of the nominal value for both within-day and between-day runs. Within-day and
between-day precision was < 15%. Recoveries of DTG and its internal standard seen with
this methodology were approximately 100%.
In order to extract DTG from RT samples, the tissue samples were homogenized in 1 mL of
80:20 water:acetonitrile. A portion of the resulting homogenate was extracted by protein
precipitation with acetonitrile containing DTG-IS. Following vortex and centrifugation
steps, a portion of the supernatant was diluted with water. Dolutegravir was detected on an
LC-MS/MS system using the same method as described for BP. During method validation,
calibration standards were prepared in human vaginal tissue homogenate. QC samples were
prepared in human vaginal and rectal tissue homogenates. Method validation results showed
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that calibration standards prepared in vaginal tissue homogenate could be used successfully
to quantitate DTG in rectal tissue samples. For sample analysis, calibration standards and
QC samples were prepared in human vaginal tissue homogenate. The dynamic range of the
assay was 0.2-200 ng/mL homogenate. The recoveries of DTG and its internal standard were
>80% in RT. All calibrators and quality controls samples were within 15% of the nominal
value with precision values < 15%. Human saliva was used as a surrogate matrix for
analysis of RF. Calibration standards and QC samples were prepared by adding human
saliva, fortified at various concentrations with DTG, onto clean swabs to mimic the
composition of the study samples. DTG was initally extracted from swabs with 2 mL
acetonitrile. A portion of the extract was then mixed with DTG-IS. Following vortex and
centrifugation steps, samples were transferred to a 96-well plate for LC-MS/MS analysis
using the same method as described for BP. Samples above the calibration range of 0.075 to
75 ng DTG per swab were diluted 20-fold and reanalyzed. All calibrators and quality control
samples were within 15% of the nominal value for both within-day and between-day runs.
Within-day and between-day precision was < 15%. Recoveries of DTG and its internal
standard seen with this methodology were >90%.
Pharmacokinetic and Statistical Analysis
Noncompartmental analysis was performed using Phoenix WinNonlin v6.3 (Certara L.P.; St.
Louis, MO). Actual times were used in all PK analyses. Area under the concentration-time
curves from 0 to 24 hours (AUC0-24hr) were calculated using the trapezoidal rule with linear
up/log down interpolation. Pharmacokinetic estimates were determined at PK1 for SF and
both PK1 and PK2 for RT using the geometric mean of concentrations at each time point. As
DTG concentrations in some RF samples were below the limit of detection (BLD),
composite AUC for RF at PK1 was calculated using median concentrations at each time
point. Since RT from two subjects was collected at each time point following single and
multiple dosing, composite profiles were used for PK analysis. Spearman Rank Correlations
between RF and RT were calculated using SAS 9.3 (SAS Institute Inc; Cary, NC). PK
parameters are separated by day and by matrix. BLD concentrations were imputed as 0 and
concentrations below the limit of quantification (BLQ) were imputed as half the lower limit
of quantification (LLOQ). Accumulation ratios were calculated from the geometric mean




14 participants were enrolled and 12 completed the study. The median age of the 12
evaluable participants was 25.5 (21-44) years. Participants had a median (range) body mass
index (BMI) of 25.0 (20.4-31.1) and weight of 78.5 (58.2-107) kg at screening. Seven
participants were African American and five were Caucasian. One participant identified his
ethnicity as Hispanic or Latino. Fourteen subjects were enrolled and evaluated for safety.
Two participants were not able to complete all protocol procedures.
Plasma Concentrations
Single and multiple dose pharmacokinetics of DTG in all matrices are presented in Table 1.
DTG achieved BP exposure in males consistent with previous reports. After a single dose,
BP DTG median (IQR) AUC0-24h was 31,335 (24,949-39,971) ng*hr/mL, with a median
(IQR) t1/2 (calculated within the 24 hour dosing interval) of 12.2 hr (11.2 - 14.2 hr). The
observed median (IQR) DTG C24h was 704 (580 - 874) ng/mL, which is approximately 11-
fold higher than the protein binding-adjusted IC90 (PA-IC90) of 64 ng/mL. Pharmacokinetic
parameters following 7 and 8 days of DTG dosing were comparable, with DTG achieving
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median (IQR) AUC0-24h accumulation ratios of 1.6 (1.5 - 1.9) and 1.3 (1.0 - 1.6),
respectively. Due to pharmacokinetic differences observed between the days, a BP median
profile was used for comparison to other matrices. On Day 8, median (IQR) AUC0-24h was
41,320 (28,092-47,219) ng*hr/mL with a median (IQR) t1/2 of 14.2 (12.0 - 16.1) hr,
respectively. On Day 8, median (IQR) BP DTG C24h was 954 (554-1093) ng/mL and
remained approximately 15-fold above the PA-IC90 of 64 ng/mL. DTG achieved a Cmax of
2285 (1790-2743) ng/mL after a single dose and 2945 (2120-3400) ng/mL after 8 doses.
Median (IQR) BP Tmax was 4 (2-5) and 2.5(1-3) hr following a single and 8 doses,
respectively. Intersubject variability in Cmax, C24h, and AUC0-24h ranged from 24-43 %CV.
Seminal Fluid Concentrations
A composite concentration vs. time profile was generated based on the geometric mean
concentrations of sparse samples after a single dose of DTG. SF reached a maximum
concentration (range) of 139.7 (85.2-254) ng/mL at 11.8 h post-dose with a t1/2 of 7.7 hr.
The observed Day 1 SF DTG AUC0-24h was 2,017.7 ng*hr/mL, representing approximately
6.6% BP exposure. SF DTG C24h ranged from 33 ng/mL to 83.4 ng/mL. The observed
median (IQR) trough concentration in SF was 41.5 (34.2-73.8) ng/mL. Single dose
concentration vs. time profiles for all matrices are presented in Figure 1.
Utilizing a composite analysis of SF collections over Day 7 and 8 of dosing, the median
(IQR) AUC0-24h was 3,229 (2439-4376) ng*hr/mL. This resulted in a median (IQR)
accumulation ratio (Rac) of 1.6 (1.2-2.2) over 7-8 days, and DTG seminal penetration that
was 6.8 (5.5-8.7) % of BP. Peak concentrations of 243.5 (189.5 - 322.5) ng/mL were
reached after 3.5 (2.8-5.8) hr. Median C24h was 57.9 (47.6-93.9) ng/mL. SF concentrations
reached a Cmax of 243.5 (189.5-322.5) ng/mL after 3.5 (3-6) hr. Concentration vs. time
profiles for all matrices following multiple doses are shown in Figure 2.
Rectal Mucosal Fluid Concentrations
In RF, a peak concentration of 17.0 ng/swab occurred at approximately 24 hours after a
single dose. AUC0-24h was 91.9 ng*hr/swab. No terminal elimination phase was observed.
In the multiple dose composite profile, a median (IQR) peak concentration of 26.5 (8.0 -
289) ng/mL occurred in RF at 12.1 (6.1-12.1) hr. Median (IQR) RF AUC0-24h was 300.0
(73.6 - 3160) ng*hr/swab and a terminal elimination phase was only quantifiable for 3
subjects. There was no detectable correlation (Spearman rho = 0.43, p = 0.17) between RF
concentrations and RT concentrations collected within a 1 hr window across Day 7 and 8.
RF exposures were low relative to RT with RF:RT AUC0-24h ratios of 0.018 and 0.047 after
single and repeat dosing.
Colorectal Tissue Concentrations
DTG penetration in RT was higher than that observed for either SF or RF. RT AUC0-24h
was 5,281 ng/g tissue on Day 1 and 7,596 ng/g tissue on Day 7-8, resulting in RT
penetration of 17% compared to BP after both single and multiple dosing. DTG was
detected in RT at 1 hour following a single dose and maintained concentrations above the
PA-IC90 over the entire dosing interval. C24h was 114.5 ng/g tissue on Day 1 and 139.1 ng/g
tissue over Day 7-8. DTG accumulated in RT after multiple doses with an Rac of 1.4.
Safety
Adverse event data includes 14 subjects who received 1 or more doses of DTG. No serious
adverse events were reported during this study and all adverse events were ≤ DAIDS grade
2. Two subjects were discontinued for reasons considered unrelated to study drug by the
study physician. One subject with a history of generalized anxiety disorder experienced a
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panic attack of moderate severity during the second PK visit. Study staff was unable to
maintain peripheral intravenous access during the first PK visit in another. Non-serious
adverse events included headaches (4 subjects) that were considered possibly related to
study drug by the investigators. One case of vascular access site soreness was reported and
considered to be unrelated to study drug. A single subject experienced transient muscle
tightness and the relation to study drug was unknown. No laboratory abnormalities equal to
or greater than DAIDS severity grade 2 were observed.
Discussion
DTG pharmacokinetics in BP are consistent with published results, with a relatively long
terminal elimination half-life and trough concentrations ranging from 6 to 34 fold above the
PAIC90 in all subjects [1,2]. Differences in exposure were observed between Day 7 and 8 of
dosing. The higher exposure on Day 7 was likely a food effect, as diet was unrestricted
during home dosing on Days 2-6 with likely higher fat content than those given in the
research unit. Consistent with this observation, DTG exposures increase from 33% to 66%
when taken with food depending on fat content of the meal [17].
DTG SF median trough concentrations are below the PA-IC90 after single and multiple
doses. Additionally, SF exposure is only ～7% of that observed in BP. These low exposures
are predicted by the high plasma protein binding of DTG and are similar to results for drugs
in other therapeutic classes [16]. The low genital tract penetration is consistent with the SF
to BP penetration ratios of other highly protein-bound ARVs including enfuvirtide (0%),
lopinavir (5%), nelfinavir (5%), ritonavir (3%), saquinavir (3%), and efavirenz (3%). Protein
binding in SF is typically lower than in BP resulting in a higher proportion of available free
drug. DTG protein binding in SF was not quantified in this study. Utilizing extremes of SF
protein binding in currently documented (8.9% to 97%), free median trough DTG
concentrations could theoretically range from 1.2 ng/mL to 37.8 ng/mL after a single dose
and from 1.7 ng/mL to 52.7 ng/mL after multiple doses [18,19]. DTG trough concentrations
would therefore be greater than 6-fold above the in vitro IC50 of 0.21 ng/mL following a
single dose. Despite the low SF concentrations, distribution to this matrix was rapid and
drug was quantifiable in all subjects at 1 hour post-dose.
Self-collected RF swabs are unlikely to be a useful surrogate for RT concentrations in future
trials. Self-collected swabs of RF were obtained in an effort to identify a substitute for
directly obtaining tissue through rectal biopsies. However, the large inter-subject variability
in RF DTG exposure is likely due to variation in self-collection by individual subjects, and
the lack of a weight or volume correction. Swabs were not corrected for weight or volume
due to expected contamination by fecal material, and due to the practicality of how these
may be collected outside of an academic research center.
Although DTG distributes rapidly into RT, the overall exposure is 17% of that observed in
BP, and lower than the other ARVs ranging from 2.7 (darunavir) to 231 (raltegravir)
[18,20]. Despite the low exposure, DTG concentrations in RT remain above the PA-IC90
across dosing intervals following single and multiple doses and trough concentrations
remain approximately 2 fold higher than the PA-IC90.
Conclusions
The BP pharmacokinetics of single and multiple doses of DTG in this investigation were
similar to previous reports [1,2]. Although DTG rapidly distributes to sites of transmission,
DTG exposure in seminal fluid and rectal tissue was considerably lower than BP and other
ARVs. Following multiple doses, DTG accumulates in vulnerable fluid and tissue, and
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maintains concentrations above the PA-IC90 in rectal tissue but only 36% of seminal fluid
samples. Further studies are warranted to determine the implications of these findings on
prevention.
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Figure 1. Concentration versus time profiles of DTG in BP, SF, RF, and RT following a single
dose
Blood plasma (○), seminal fluid (□), colorectal tissue (◊), and rectal mucosal fluid (Δ) are
presented as median (IQR).
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Figure 2. Concentration versus time profiles of DTG in BP, SF, RF, and RT following multiple
doses
Blood plasma (○), seminal fluid (□), colorectal tissue (◊), and rectal mucosal fluid (Δ) are
presented as median (IQR).
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